A physician and pharmaceutical researcher, Dr. Erol Onel serves as the vice president of Heron Therapeutics, Inc. In this capacity, he works with a team of professionals as they seek approval for a long-acting non-opioid drug. Over the years, Dr. Erol Onel has belonged to several professional organizations, including the American Urological Association (AUA).
Dedicated to improving urologic care through research, policy, and education, the AUA recently released new joint clinical guidelines for the treatment of stress urinary incontinence (SUI). This condition affects nearly 50 percent of women in the United States and is signified by involuntary urine leakage due to sneezing, laughing, or other activities that increase abdominal pressure. In many cases, women opt for surgical treatment of SUI symptoms.
The AUA wrote the joint evidence-based guidelines for surgical treatment with the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU). They include a total of 24 treatment recommendations, including alternatives to various surgical options and information about determining when additional evaluations are needed to confirm SUI. A panel of SUI experts worked on creating the clinical guideline, and it was subject to 93 peer reviews before being approved and released by the AUA and SUFU.